⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MIST News
Milestone Pharmaceuticals Inc. Common Shares
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session
globenewswire.com
MIST
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session
globenewswire.com
MIST
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
globenewswire.com
MIST
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
globenewswire.com
MIST
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
globenewswire.com
MIST
Singular Research Emerging Growth & Value Leaders Webinar Thursday, February 19, 2026 Ready to Announce with Confidence?
newsfilecorp.com
RAIN
FLNT
VTIX
MIST
ACU
LRN
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
globenewswire.com
MIST
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
MIST
Industrial Radiography Industry Research Report 2026 - Global Market Size, Share, Trends, Opportunity, and Forecast, 2021-2025 & 2026-2031
globenewswire.com
BKR
OII
MIST
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
globenewswire.com
MIST